Truscreen Group Ltd Total Liabilities
Truscreen Group Ltd total liabilities. Based on the latest financial reports, Truscreen Group Ltd (TRU) has total liabilities worth AU$951.80K AUD (≈ $673.46K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Truscreen Group Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Truscreen Group Ltd (2013–2024)
Total liabilities of Truscreen Group Ltd from 2013 to 2024. This chart illustrates how Truscreen Group Ltd's total liabilities have evolved over time, based on quarterly financial data.
Truscreen Group Ltd Competitors by Total Liabilities
The table below lists competitors of Truscreen Group Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HELIX Resources Ltd
AU:HLX
|
Australia | AU$753.28K |
|
Thai Ha Public Company Limited
BK:KASET
|
Thailand | ฿419.03 Million |
|
Tyranna Resources Ltd
AU:TYX
|
Australia | AU$138.07K |
|
Metal Bank Ltd
AU:MBK
|
Australia | AU$334.64K |
|
PURE ENERGY MINLS
F:AHG
|
Germany | €249.45K |
|
Future Consumer Limited
NSE:FCONSUMER
|
India | Rs8.53 Billion |
|
Brilliant Future AB
ST:BRILL
|
Sweden | Skr46.11 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Truscreen Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Truscreen Group Ltd asset portfolio.
Liquidity & Leverage Metrics
Truscreen Group Ltd Total Liabilities Ratios Explained
Truscreen Group Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Truscreen Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Truscreen Group Ltd (2013–2024)
The table below shows the annual total liabilities of Truscreen Group Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$839.98K ≈ $594.34K |
+5.20% |
| 2023-12-31 | AU$798.45K ≈ $564.95K |
-13.98% |
| 2022-12-31 | AU$928.16K ≈ $656.73K |
-6.43% |
| 2021-12-31 | AU$991.89K ≈ $701.83K |
+42.62% |
| 2020-12-31 | AU$695.50K ≈ $492.11K |
-16.50% |
| 2019-12-31 | AU$832.94K ≈ $589.36K |
-32.00% |
| 2018-12-31 | AU$1.22 Million ≈ $866.73K |
+122.33% |
| 2017-12-31 | AU$550.97K ≈ $389.84K |
-23.18% |
| 2016-12-31 | AU$717.19K ≈ $507.46K |
+67.01% |
| 2015-12-31 | AU$429.43K ≈ $303.85K |
-45.45% |
| 2014-12-31 | AU$787.21K ≈ $557.00K |
-28.32% |
| 2013-12-31 | AU$1.10 Million ≈ $777.05K |
-- |
About Truscreen Group Ltd
TruScreen Group Limited, together with its subsidiaries, develops, manufacture, and sale of cancer detection devices and systems in Mexico, China, Russia, Vietnam, Zimbabwe, and the Middle East/North Africa. It offers the TruScreen cervical cancer screening device, a medical device for identifying and detecting the presence of precancerous and cancerous tissue on the cervix in real time. The comp… Read more